Literature DB >> 20873973

Performance of the Framingham and SCORE cardiovascular risk prediction functions in a non-diabetic population of a Spanish health care centre: a validation study.

Lourdes Cañón Barroso1, Eloísa Cruces Muro, Natalio Díaz Herrera, Gerardo Fernández Ochoa, Juan Ignacio Calvo Hueros, Francisco Buitrago.   

Abstract

OBJECTIVE: To analyse the 10-year performance of the original Framingham coronary risk function and of the SCORE cardiovascular death risk function in a non-diabetic population of 40-65 years of age served by a Spanish healthcare centre. Also, to estimate the percentage of patients who are candidates for antihypertensive and lipid-lowering therapy.
DESIGN: Longitudinal, observational study of a retrospective cohort followed up for 10 years.
SETTING: Primary care health centre. PATIENTS: A total of 608 non-diabetic patients of 40-65 years of age (mean 52.8 years, 56.7% women), without evidence of cardiovascular disease were studied. MAIN OUTCOME MEASURES: Coronary risk at 10 years from the time of their recruitment, using the tables based on the original Framingham function, and of their 10-year risk of fatal cardiovascular disease using the SCORE tables.
RESULTS: The actual incidence rates of coronary and fatal cardiovascular events were 7.9% and 1.5%, respectively. The original Framingham equation over-predicted risk by 64%, while SCORE function over-predicted risk by 40%, but the SCORE model performed better than the Framingham one for discrimination and calibration statistics. The original Framingham function classified 18.3% of the population as high risk and SCORE 9.2%. The proportions of patients who would be candidates for lipid-lowering therapy were 31.0% and 23.8% according to the original Framingham and SCORE functions, respectively, and 36.8% and 31.2% for antihypertensive therapy.
CONCLUSION: The SCORE function showed better values than the original Framingham function for each of the discrimination and calibration statistics. The original Framingham function selected a greater percentage of candidates for antihypertensive and lipid-lowering therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20873973      PMCID: PMC3444797          DOI: 10.3109/02813432.2010.518407

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  28 in total

1.  Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study.

Authors:  A Menotti; P E Puddu; M Lanti
Journal:  Eur Heart J       Date:  2000-03       Impact factor: 29.983

2.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

3.  [Coronary risk estimation in Spain using a calibrated Framingham function].

Authors:  Jaume Marrugat; Pascual Solanas; Ralph D'Agostino; Lisa Sullivan; José Ordovas; Ferran Cordón; Rafael Ramos; Joan Sala; Rafael Masià; Izabella Rohlfs; Roberto Elosua; William B Kannel
Journal:  Rev Esp Cardiol       Date:  2003-03       Impact factor: 4.753

4.  Too much doing and too little thinking in medical science!

Authors:  Linn Getz; Anna Luise Kirkengen; Irene Hetlevik
Journal:  Scand J Prim Health Care       Date:  2008       Impact factor: 2.581

5.  Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart.

Authors:  A Menotti; M Lanti; P E Puddu; D Kromhout
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

6.  A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study.

Authors:  Troels F Thomsen; Dan McGee; Michael Davidsen; Torben Jørgensen
Journal:  Int J Epidemiol       Date:  2002-08       Impact factor: 7.196

7.  An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study.

Authors:  Gary S Collins; Douglas G Altman
Journal:  BMJ       Date:  2010-05-13

8.  Patients prefer pictures to numbers to express cardiovascular benefit from treatment.

Authors:  Felicity Goodyear-Smith; Bruce Arroll; Lydia Chan; Rod Jackson; Sue Wells; Timothy Kenealy
Journal:  Ann Fam Med       Date:  2008 May-Jun       Impact factor: 5.166

9.  Secular trends in cardiovascular risk factors with a 36-year perspective: observations from 38- and 50-year-olds in the Population Study of Women in Gothenburg.

Authors:  Cecilia Björkelund; Dominique Andersson-Hange; Kate Andersson; Calle Bengtsson; Ann Blomstrand; Dorota Bondyr-Carlsson; Gabriele Eiben; Kerstin Rödström; Agneta Sjöberg; Valter Sundh; Lilian Weman; Dimitri Zylberstein; Magnus Hakeberg; Lauren Lissner
Journal:  Scand J Prim Health Care       Date:  2008       Impact factor: 2.581

10.  An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study.

Authors:  Gary S Collins; Douglas G Altman
Journal:  BMJ       Date:  2009-07-07
View more
  11 in total

1.  Prevalence, awareness, treatment, and control of hypertension: rule of thirds in the Skaraborg project.

Authors:  Ulf Lindblad; Johanna Ek; Jenny Eckner; Charlotte A Larsson; Guangliang Shan; Lennart Råstam
Journal:  Scand J Prim Health Care       Date:  2012-06       Impact factor: 2.581

2.  Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative.

Authors:  Nancy R Cook; Nina P Paynter; Charles B Eaton; JoAnn E Manson; Lisa W Martin; Jennifer G Robinson; Jacques E Rossouw; Sylvia Wassertheil-Smoller; Paul M Ridker
Journal:  Circulation       Date:  2012-03-07       Impact factor: 29.690

3.  Effect of Aerobic and Resistance Exercise Intervention on Cardiovascular Disease Risk in Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Authors:  Kyuwan Lee; Debu Tripathy; Wendy Demark-Wahnefried; Kerry S Courneya; Nathalie Sami; Leslie Bernstein; Darcy Spicer; Thomas A Buchanan; Joanne E Mortimer; Christina M Dieli-Conwright
Journal:  JAMA Oncol       Date:  2019-05-01       Impact factor: 31.777

4.  Is the use of cholesterol in mortality risk algorithms in clinical guidelines valid? Ten years prospective data from the Norwegian HUNT 2 study.

Authors:  Halfdan Petursson; Johann A Sigurdsson; Calle Bengtsson; Tom I L Nilsen; Linn Getz
Journal:  J Eval Clin Pract       Date:  2011-09-25       Impact factor: 2.431

5.  Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study.

Authors:  Louise Gek Huang Goh; Timothy Alexander Welborn; Satvinder Singh Dhaliwal
Journal:  BMC Womens Health       Date:  2014-09-26       Impact factor: 2.809

6.  Beneficial changes on plasma apolipoproteins A and B, high density lipoproteins and oxidized low density lipoproteins in obese women after bariatric surgery: comparison between gastric bypass and sleeve gastrectomy.

Authors:  J M Gómez-Martin; J A Balsa; E Aracil; M Cuadrado-Ayuso; M Rosillo; G De la Peña; M A Lasunción; H F Escobar-Morreale; J I Botella-Carretero
Journal:  Lipids Health Dis       Date:  2018-06-20       Impact factor: 3.876

7.  A 10- and 15-year performance analysis of ESC/EAS and ACC/AHA cardiovascular risk scores in a Southern European cohort.

Authors:  Cátia Santos-Ferreira; Rui Baptista; Manuel Oliveira-Santos; José Pereira Moura; Lino Gonçalves
Journal:  BMC Cardiovasc Disord       Date:  2020-06-19       Impact factor: 2.298

8.  Prediction for cardiovascular diseases based on laboratory data: An analysis of random forest model.

Authors:  Xi Su; Yongyong Xu; Zhijun Tan; Xia Wang; Peng Yang; Yani Su; Yangyang Jiang; Sijia Qin; Lei Shang
Journal:  J Clin Lab Anal       Date:  2020-07-29       Impact factor: 2.352

9.  Which patient and treatment factors are related to successful cardiovascular risk score reduction in general practice? Results from a randomized controlled trial.

Authors:  Ans H Tiessen; Andries J Smit; Jan Broer; Klaas H Groenier; Klaas Van der Meer
Journal:  BMC Fam Pract       Date:  2013-08-23       Impact factor: 2.497

10.  Cardiovascular risk assessment by FRS and SCORE in Iranian adult population.

Authors:  Alipasha Meysamie; Fereshteh Salarvand; MirHojjat Khorasanizadeh; Reza Ghalehtaki; Mahsa Eskian; Saeed Ghodsi; Shirin Ghalehtaki; Mehrshad Abbasi; Koroush Etemad; Fereshteh Asgari; Alireza Esteghamati
Journal:  J Diabetes Metab Disord       Date:  2017-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.